Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Manzanilla Sophia vs Meticel Ofteno for Eye Soothing
NCT06373653Phase 4
Key facts
- Status
- Withdrawn
- Start
- Feb 2025
- Primary completion
- Feb 2025
- Sponsor
- Laboratorios Sophia
- Modality
- Small Molecules
- Drugs
- Manzanilla Sophia
- Conditions
- asthenopia
01
Overview
Phase 4, randomised trial of Manzanilla Sophia in asthenopia (2 arms), sponsored by Laboratorios Sophia. Primary endpoint: Analog visual eyestrain test score at Day 8. Planned start Feb 2025; status: withdrawn.
02
Design
2 arms- Study design
- Randomized
Manzanilla Sophia®
Matricaria recutita 0.025% QID for 7 days
Meticel Ofteno®
Hypromellose 0.5% QID for 7 days
03
Who it enrols
Adults with eye strain (score >= 3 on 4 questions) willing to comply with visits. Excludes recent contact lens users, pregnant women, and those with history of drug addiction.
04
Endpoints
Primary
Analog visual eyestrain test score
Secondary
Incidence of unexpected adverse events related to the interventions
Incidence of conjunctival hyperemia
Incidence of sensation of ocular dryness
Incidence of ocular irritation
Incidence of sensation of (sleep-crust)
Incidence of sensation of comfort with the application
Beyond the preview
Go deeper on NCT06373653.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06373653.